Previous 10 | Next 10 |
The following slide deck was published by Caladrius Biosciences, Inc. in conjunction with their 2020 Q1 earnings Read more ...
Caladrius Biosciences, Inc. (CLBS) Q1 2020 Earnings Conference Call May 07, 2020, 16:30 ET Company Participants John Menditto - VP, IR & Corporate Communications David Mazzo - President, CEO & Director Joseph Talamo - CFO & SVP Douglas Losordo - EVP, Global Head, R&...
Caladrius Biosciences (NASDAQ: CLBS ): Q1 GAAP EPS of -$0.38 beats by $0.06 . More news on: Caladrius Biosciences, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Company initiates development of CLBS119 for the repair of COVID-19 induced lung damage and expands its proprietary CD34+ cell therapy portfolio Adds ~$16 million in funding bringing current cash to ~$34 million Conference call begins today at 4:30 p.m. Eastern time BASKING RID...
BASKING RIDGE, N.J., May 06, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disease...
BASKING RIDGE, N.J., April 30, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disea...
BASKING RIDGE, N.J., April 27, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disea...
BASKING RIDGE, N.J., April 23, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, cardi...
CounterPath (NASDAQ: CPAH ) +91% on Q4 update . More news on: CounterPath Corporation, Borqs Technologies, Inc., Immunomedics, Inc., Stocks on the move, Read more ...
BASKING RIDGE, N.J., April 23, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse, not manage, disea...
News, Short Squeeze, Breakout and More Instantly...
Caladrius Biosciences Inc. Company Name:
CLBS Stock Symbol:
NASDAQ Market:
Caladrius Biosciences Inc. Website:
BASKING RIDGE, N.J., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), announced today that, based upon the final vote count certified by the independent inspector of elections for the annual meeting of ...
NEW YORK, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the upcoming Life Sciences Virtual Investor Conference to be held on September 15 th . Individual investors, institutional ...
BASKING RIDGE, N.J., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, today announced tha...